Urinary bladder disorders

FemPulse Announces Issuance of Patents in China and Australia

Retrieved on: 
Monday, January 6, 2020
Urinary bladder disorders, RTT, Overactive bladder, Peripheral nervous system, Nerve plexus, OAB, Urinary bladder

MINNEAPOLIS, Jan. 06, 2020 (GLOBE NEWSWIRE) -- FemPulse Corporation (FemPulse), a private, clinical-stage bioelectronic medicine company developing a novel therapy for the personalized treatment of overactive bladder (OAB) in women, today announced the issuance of two patents from China and Australia covering methods of stimulation of autonomic nerve plexuses in women.

Key Points: 
  • MINNEAPOLIS, Jan. 06, 2020 (GLOBE NEWSWIRE) -- FemPulse Corporation (FemPulse), a private, clinical-stage bioelectronic medicine company developing a novel therapy for the personalized treatment of overactive bladder (OAB) in women, today announced the issuance of two patents from China and Australia covering methods of stimulation of autonomic nerve plexuses in women.
  • 2018200589, also entitled Devices and Methods For Stimulating Nerves, encompassing claims regarding important aspects of the FemPulse wearable therapy.
  • The granted patents further position FemPulse to be able to operate globally as we continue to advance product development.
  • The addition of these patents increases FemPulses domestic and international portfolio to seven issued patents.

Urovant Sciences Announces Submission of New Drug Application for Vibegron for the Treatment of Overactive Bladder

Retrieved on: 
Monday, December 30, 2019
Biotechnology, Pharmaceutical, Health, Medical specialties, Medicine, Urinary bladder disorders, RTT, Overactive bladder, Urology, Urinary incontinence, Urinary bladder, OAB, Beta3-adrenergic agonist, Percutaneous tibial nerve stimulation, Vibegron:, Urovant Sciences, Sumitomo Dainippon Pharma Co., Ltd.

The NDA for vibegron is supported by an extensive clinical development program, which included over 4,000 patients with OAB.

Key Points: 
  • The NDA for vibegron is supported by an extensive clinical development program, which included over 4,000 patients with OAB.
  • The symptoms of overactive bladder affect over 30 million people in the U.S. Vibegron, if approved next year, would be the first new branded prescription drug for the treatment of OAB in nearly a decade.
  • Vibegron is a once-daily beta-3 adrenergic agonist under investigation for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
  • The Companys lead product candidate, vibegron, an oral, once-daily small molecule beta-3 agonist is being evaluated for overactive bladder (OAB).

FemPulse Secures Equity Financing to Finalize Development of Proprietary Bioelectronic Device for Treatment of Overactive Bladder in Women

Retrieved on: 
Thursday, December 5, 2019
Branches of biology, Health sciences, Organ systems, Urinary bladder disorders, Gynaecology, RTT, Neurotechnology, Overactive bladder, Neuromodulation, Vagina, Therapy, OAB

Participants in the round included several new investors with significant global business, finance and biotech expertise, as well as continued strong support from existing investors.

Key Points: 
  • Participants in the round included several new investors with significant global business, finance and biotech expertise, as well as continued strong support from existing investors.
  • FemPulse therapy is a minimally invasive, bioelectronic medicine solution for the treatment of OAB in women being developed as an alternative to conventional, invasive neuromodulation therapies.
  • FemPulse Corporation is a privately held clinical-stage bioelectronic medicine company focused on treating women with overactive bladder.
  • The small, vaginal ring is disposable and may remain indwelling for days or weeks, affording discreet, personalized, continuous and self-managed therapy.

United States Overactive Bladder (Anticholinergics & Beta Adrenoreceptor Agonists) Market Insights, Trends and Forecasts, 2019-2021 & 2031 - ResearchAndMarkets.com

Retrieved on: 
Friday, November 8, 2019
General Health, Pharmaceutical, Health, Psychoactive drugs, Drugs, Neurochemistry, RTT, Muscarinic antagonists, Urinary bladder disorders, Overactive bladder, Chloroarenes, Amines, OAB, Trend, Ketamine

The "US Overactive Bladder (Anticholinergics & Beta Adrenoreceptor Agonists) Market Report: Insights, Trends and Forecast (2021-2031)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Overactive Bladder (Anticholinergics & Beta Adrenoreceptor Agonists) Market Report: Insights, Trends and Forecast (2021-2031)" report has been added to ResearchAndMarkets.com's offering.
  • The U.S. OAB market is estimated to reach US$3.49 billion in 2031, growing at a CAGR of 5.01%, for the period spanning from 2021-2031.
  • A few notable trends include advancing innovative therapies, rising awareness of overactive bladder, growing adoption of procedural (third line) therapy, development of gene therapy and progressing drug pipeline.
  • The market dynamics such as growth drivers, market trends and challenges are analysed in-depth.

Go with the Flow for Bladder Health Awareness Month

Retrieved on: 
Friday, November 1, 2019
Medical specialties, Medicine, Clinical medicine, RTT, Urinary bladder disorders, Urology, Toilet training, Urine, Overactive bladder, Urinary incontinence, Nocturia, Bladder cancer

BALTIMORE, Nov. 1, 2019 /PRNewswire/ -- November is Bladder Health Awareness Month and while many of us are not always thinking about our bladder health, this month serves as a reminder to get the facts about common bladder health conditions and to take an active role in caring for our bladder health.

Key Points: 
  • BALTIMORE, Nov. 1, 2019 /PRNewswire/ -- November is Bladder Health Awareness Month and while many of us are not always thinking about our bladder health, this month serves as a reminder to get the facts about common bladder health conditions and to take an active role in caring for our bladder health.
  • There are many conditions that fall within this category, including urinary incontinence, overactive bladder, bladder cancer, bedwetting and nocturia, to name a few.
  • This is why the Urology Care Foundation has created a Urology Care Foundation Bladder Health Info Center where a wide variety of free bladder health videos, fact sheets, posters, social media messages, brochures and podcasts can be found.
  • For more information about bladder health, please contact the AUA Communications office by calling 410-689-3932 or sending email to [email protected] .

Urovant Sciences Initiates Part 2 of Phase 3 COURAGE Study of Vibegron for Overactive Bladder in Men with Benign Prostatic Hyperplasia

Retrieved on: 
Monday, October 21, 2019
Seniors, MEN, Clinical trials, Biotechnology, Other Health, Health, Consumer, Pharmaceutical, General Health, RTT, Urinary bladder disorders, Overactive bladder, Chemical compounds, Benign prostatic hyperplasia, Medical specialties, Aromatic compounds, BPH, OAB, Solabegron, Beta3-adrenergic agonist, the COURAGE Phase 3 Trial, Urovant Sciences

This is a pivotal milestone for this development program as there are currently no FDA-approved products specifically indicated for the treatment of overactive bladder in men with BPH.

Key Points: 
  • This is a pivotal milestone for this development program as there are currently no FDA-approved products specifically indicated for the treatment of overactive bladder in men with BPH.
  • The COURAGE study is a randomized, double blind, placebo-controlled trial in men who are experiencing OAB symptoms, while also taking BPH medications.
  • Urovant recently reported positive long-term data for its lead product candidate, vibegron, an oral, once-daily small molecule beta-3 agonist being evaluated for overactive bladder (OAB).
  • In addition, vibegron is being evaluated in a phase 3 study for the treatment of OAB in men with benign prostatic hyperplasia and in a phase 2a study for abdominal pain associated with irritable bowel syndrome.

Growth of Interstitial Cystitis Drugs Market to be impacted by the Advent of Gene Therapy | Technavio

Retrieved on: 
Friday, October 18, 2019
Health, Pharmaceutical, Medical specialties, Urology, Organ systems, Urinary bladder disorders, Infectious diseases, Interstitial cystitis, RTT, Interstitial, Urinary tract infection, Urinary bladder, Emphysematous cystitis, Urethral syndrome

Interstitial Cystitis Drugs Market Landscape 2019-2023: Geographic landscape

Key Points: 
  • Interstitial Cystitis Drugs Market Landscape 2019-2023: Geographic landscape
    Interstitial Cystitis Drugs Market Landscape 2019-2023: Type
    Register for a free trial today and gain instant access to 10,000+ market research reports.
  • Patients suffering from interstitial cystitis experience symptoms such as lower urinary tract issues and bladder pain.
  • The increasing number of interstitial cystitis cases is driving the demand for interstitial cystitis drugs.
  • Most of the interstitial cystitis drugs and off-label drugs are small molecules and have failed to fully cure the disease.

Georgia Urology's Dr. Jeffrey Proctor hosts ICA Walk for an IC Cure in Cartersville

Retrieved on: 
Friday, October 18, 2019
Urinary bladder disorders, Acworth, Interstitial cystitis, Ic, Interstitial, Cartersville, Georgia, Dellinger, Medical specialties, Medicine

CATERSVILLE, Ga., Oct. 18, 2019 /PRNewswire-PRWeb/ -- Georgia Urology's Dr. Jeffrey Proctor, an expert in the field of interstitial cystitis (IC), will be speaking at the ICA Walk for an IC Cure taking place Nov. 2 at Dellinger Park.

Key Points: 
  • CATERSVILLE, Ga., Oct. 18, 2019 /PRNewswire-PRWeb/ -- Georgia Urology's Dr. Jeffrey Proctor, an expert in the field of interstitial cystitis (IC), will be speaking at the ICA Walk for an IC Cure taking place Nov. 2 at Dellinger Park.
  • Dr. Proctor treats IC at Georgia Urology's Acworth and Cartersville locations.
  • "More than 12 million people in the US suffer from IC, and it can affect anyone," says Dr. Proctor.
  • Events such as the ICA Walk for an IC Cure will help get us there, one step at a time."

Bioness Announces Preliminary European Post-Approval Results of StimRouter® Neuromodulation System for the Treatment of Overactive Bladder at the 49th International Continence Society Annual Meeting

Retrieved on: 
Tuesday, September 3, 2019
Branches of biology, Organ systems, Neuroscience, Urinary bladder disorders, Neurophysiology, RTT, Neurotechnology, Overactive bladder, Neuromodulation, Urinary bladder, OAB, Percutaneous tibial nerve stimulation

Bioness is exhibiting at booth 5A to discuss the StimRouter Neuromodulation System's success with Overactive Bladder(OAB) and the device's effectivenessin treating chronic pelvic pain in Europe, Australia, and the United States.

Key Points: 
  • Bioness is exhibiting at booth 5A to discuss the StimRouter Neuromodulation System's success with Overactive Bladder(OAB) and the device's effectivenessin treating chronic pelvic pain in Europe, Australia, and the United States.
  • Overactive bladder affects approximately 546 million people worldwide andmay lead to the involuntary loss of urine (incontinence).
  • Aachen UniversityHospital is the first hospital in Europe that is implanting the StimRouter for the treatment for OAB.
  • The StimRouter is the first FDA-cleared, minimally-invasive, long-term neuromodulation medical device indicated to treat chronic pain of a peripheral nerve origin.

Bioness Announces Preliminary European Post-Approval Results of StimRouter® Neuromodulation System for the Treatment of Overactive Bladder at the 49th International Continence Society Annual Meeting

Retrieved on: 
Tuesday, September 3, 2019
Branches of biology, Organ systems, Neuroscience, Urinary bladder disorders, Neurophysiology, RTT, Neurotechnology, Overactive bladder, Neuromodulation, Urinary bladder, OAB, Percutaneous tibial nerve stimulation

Bioness is exhibiting at booth 5A to discuss the StimRouter Neuromodulation System's success with Overactive Bladder(OAB) and the device's effectivenessin treating chronic pelvic pain in Europe, Australia, and the United States.

Key Points: 
  • Bioness is exhibiting at booth 5A to discuss the StimRouter Neuromodulation System's success with Overactive Bladder(OAB) and the device's effectivenessin treating chronic pelvic pain in Europe, Australia, and the United States.
  • Overactive bladder affects approximately 546 million people worldwide andmay lead to the involuntary loss of urine (incontinence).
  • Aachen UniversityHospital is the first hospital in Europe that is implanting the StimRouter for the treatment for OAB.
  • The StimRouter is the first FDA-cleared, minimally-invasive, long-term neuromodulation medical device indicated to treat chronic pain of a peripheral nerve origin.